Boothbay Fund Management LLC Purchases Shares of 24,722 Vera Therapeutics, Inc. (NASDAQ:VERA)

Boothbay Fund Management LLC bought a new position in Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) in the fourth quarter, according to its most recent disclosure with the SEC. The firm bought 24,722 shares of the company's stock, valued at approximately $1,045,000.

Several other institutional investors have also modified their holdings of VERA. SG Americas Securities LLC grew its holdings in shares of Vera Therapeutics by 116.7% in the fourth quarter. SG Americas Securities LLC now owns 20,270 shares of the company's stock valued at $857,000 after purchasing an additional 10,916 shares during the period. Lord Abbett & CO. LLC grew its stake in shares of Vera Therapeutics by 41.1% in the 3rd quarter. Lord Abbett & CO. LLC now owns 426,014 shares of the company's stock valued at $18,830,000 after buying an additional 124,197 shares during the period. Barclays PLC increased its holdings in shares of Vera Therapeutics by 94.1% during the 3rd quarter. Barclays PLC now owns 85,395 shares of the company's stock worth $3,774,000 after buying an additional 41,394 shares during the last quarter. Raymond James Financial Inc. acquired a new position in Vera Therapeutics in the fourth quarter valued at approximately $2,948,000. Finally, Victory Capital Management Inc. grew its position in Vera Therapeutics by 515.0% in the fourth quarter. Victory Capital Management Inc. now owns 235,267 shares of the company's stock worth $9,949,000 after acquiring an additional 197,014 shares during the period. Hedge funds and other institutional investors own 99.21% of the company's stock.

Vera Therapeutics Stock Down 0.4 %

Shares of Vera Therapeutics stock traded down $0.09 during trading hours on Monday, reaching $25.22. 223,234 shares of the company were exchanged, compared to its average volume of 749,699. The firm has a market cap of $1.61 billion, a PE ratio of -9.69 and a beta of 1.28. The company has a debt-to-equity ratio of 0.17, a quick ratio of 13.76 and a current ratio of 13.76. Vera Therapeutics, Inc. has a 1 year low of $18.53 and a 1 year high of $51.61. The stock's fifty day moving average is $24.82 and its 200 day moving average is $35.26.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last posted its quarterly earnings results on Wednesday, February 26th. The company reported ($0.72) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.83) by $0.11. As a group, equities research analysts forecast that Vera Therapeutics, Inc. will post -2.89 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the company. JPMorgan Chase & Co. reduced their target price on Vera Therapeutics from $77.00 to $71.00 and set an "overweight" rating on the stock in a research report on Tuesday, March 4th. Wolfe Research started coverage on shares of Vera Therapeutics in a research report on Tuesday, February 4th. They issued an "outperform" rating and a $49.00 target price on the stock. Guggenheim lifted their price target on shares of Vera Therapeutics from $59.00 to $61.00 and gave the company a "buy" rating in a research report on Thursday, February 27th. The Goldman Sachs Group began coverage on shares of Vera Therapeutics in a report on Tuesday, January 28th. They issued a "buy" rating and a $58.00 target price for the company. Finally, HC Wainwright initiated coverage on Vera Therapeutics in a research note on Monday. They set a "buy" rating and a $75.00 price target on the stock. One investment analyst has rated the stock with a hold rating, seven have assigned a buy rating and three have assigned a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus price target of $65.70.

Vera Therapeutics Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.